GB2590485B - Nanoparticle conjugation - Google Patents
Nanoparticle conjugation Download PDFInfo
- Publication number
- GB2590485B GB2590485B GB1918898.6A GB201918898A GB2590485B GB 2590485 B GB2590485 B GB 2590485B GB 201918898 A GB201918898 A GB 201918898A GB 2590485 B GB2590485 B GB 2590485B
- Authority
- GB
- United Kingdom
- Prior art keywords
- nanoparticle conjugation
- nanoparticle
- conjugation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000021615 conjugation Effects 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N2021/258—Surface plasmon spectroscopy, e.g. micro- or nanoparticles in suspension
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/55—Specular reflectivity
- G01N21/552—Attenuated total reflection
- G01N21/553—Attenuated total reflection and using surface plasmons
- G01N21/554—Attenuated total reflection and using surface plasmons detecting the surface plasmon resonance of nanostructured metals, e.g. localised surface plasmon resonance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Nanotechnology (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1918898.6A GB2590485B (en) | 2019-12-19 | 2019-12-19 | Nanoparticle conjugation |
| PCT/GB2020/053285 WO2021123806A1 (en) | 2019-12-19 | 2020-12-18 | Nanoparticle conjugation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1918898.6A GB2590485B (en) | 2019-12-19 | 2019-12-19 | Nanoparticle conjugation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB201918898D0 GB201918898D0 (en) | 2020-02-05 |
| GB2590485A GB2590485A (en) | 2021-06-30 |
| GB2590485B true GB2590485B (en) | 2022-04-13 |
Family
ID=69322810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1918898.6A Expired - Fee Related GB2590485B (en) | 2019-12-19 | 2019-12-19 | Nanoparticle conjugation |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB2590485B (en) |
| WO (1) | WO2021123806A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016085911A1 (en) * | 2014-11-26 | 2016-06-02 | Washington University | Bioplasmonic detection of biomarkers in body fluids using peptide recognition elements |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120101007A1 (en) * | 2009-04-08 | 2012-04-26 | Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizebeth Nea | Silver nanoplates |
| US20130189793A1 (en) * | 2012-01-20 | 2013-07-25 | Wei Qian | Stable Colloidal Suspensions Of Gold Nanoconjugates And The Method For Preparing The Same |
| KR102654470B1 (en) * | 2017-01-30 | 2024-04-05 | 조에티스 서비시즈 엘엘씨 | Solution-based plasmon specific-binding partner assays and metallic nanostructures |
-
2019
- 2019-12-19 GB GB1918898.6A patent/GB2590485B/en not_active Expired - Fee Related
-
2020
- 2020-12-18 WO PCT/GB2020/053285 patent/WO2021123806A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016085911A1 (en) * | 2014-11-26 | 2016-06-02 | Washington University | Bioplasmonic detection of biomarkers in body fluids using peptide recognition elements |
Also Published As
| Publication number | Publication date |
|---|---|
| GB201918898D0 (en) | 2020-02-05 |
| WO2021123806A1 (en) | 2021-06-24 |
| GB2590485A (en) | 2021-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278990A (en) | Camptothecin conjugates | |
| ZA201904269B (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| ZA201705923B (en) | Drug conjugates comprising antibodies against claudin 18.2 | |
| IL277017A (en) | Nanoparticle compositions | |
| PL3544636T3 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| GB201702031D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| IL272625A (en) | Pyrrolobenzodiazepine conjugates | |
| IL269945B (en) | Pyrrolobenzodiazepine conjugates | |
| IL293095B1 (en) | Directed conjugation technologies | |
| GB201601004D0 (en) | Nanoparticle conjugates | |
| GB202112888D0 (en) | Nanoparticle | |
| GB201820626D0 (en) | Conjugates | |
| IL288681A (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| GB2590485B (en) | Nanoparticle conjugation | |
| GB201914728D0 (en) | Nanoparticle assembly | |
| GB201906997D0 (en) | Conjugates | |
| GB201900735D0 (en) | Conjugates | |
| GB201811335D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| GB201811332D0 (en) | Pyrroloobenzodiazepine-antibody conjugates | |
| GB201721290D0 (en) | Conjugates | |
| GB201719906D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| GB201719391D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| GB201719393D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| GB201719398D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| GB201721337D0 (en) | Pyrrolobenzodiazepine conjugates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20231219 |